<DOC>
	<DOC>NCT01342796</DOC>
	<brief_summary>This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a conventional subunit vaccine in previously unvaccinated children aged 6 to &lt;36 months.</brief_summary>
	<brief_title>Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Male and female previously unvaccinated healthy children aged 6 to &lt;36 months. Any known or suspected impairment of the immune system, any serious disease. Any subjects receiving licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study. Individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cell mediated immunity</keyword>
	<keyword>cell mediated immune response</keyword>
	<keyword>Children</keyword>
	<keyword>adjuvanted</keyword>
</DOC>